Anatomical and Functional Outcomes of Vitrectomy with/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment

Table 2

MTX use versus anatomical outcome in each subgroup and no MTX use versus anatomical outcome in control.

		Anatomical outcome		value
		Successful	Recurrent
Subgroups based on MTX indication	IA	26	4	0.2
	I	31	11
	IIA	28	2	0.07
	II	27	8
	IIIA	23	6	0.07
	III	23	1

MTX, methotrexate. is significant at <0.05.